Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...

A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have type 2 diabetes ...

Semaglutide, the active ingredient in popular weight loss drugs Ozempic and Wegovy, might also double as a brain booster. Research out today describes a link between semaglutide use and a reduced ...

Popular diabetes and weight loss drug, semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. The corresponding study was published in ...

Weight loss jabs such as Wegovy and Mounjaro may offer a protective effect against dementia and stroke, according to a new study.

Semaglutide, the active ingredient in diabetes medications Ozempic and Wegovy, was associated with a significantly reduced risk of developing Alzheimer's disease-related dementia among patients ...

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D).

Ozempic and the brain As much as GLP-1 agonists like Ozempic and Wegovy have gained cultural relevance as weight-loss drugs, they were originally approved to treat diabetes. The GLP-1 receptor in ...